These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 12693146)

  • 1. [The future of peptic ulcer disease without Helicobacter].
    Lehmann FS; Gyr N
    Praxis (Bern 1994); 2003 Mar; 92(12):547-50. PubMed ID: 12693146
    [No Abstract]   [Full Text] [Related]  

  • 2. [Selective Cox-2 inhibitor in osteoarthritis and rheumatoid arthritis. No increased risk for the heart].
    MMW Fortschr Med; 2003 Mar; 145(11):60. PubMed ID: 12688204
    [No Abstract]   [Full Text] [Related]  

  • 3. [Specific cyclo-oxygenase inhibitors. 2. Gastric toxicity?].
    Blondon H
    Presse Med; 2000 Mar; 29(9):482-3. PubMed ID: 10745938
    [No Abstract]   [Full Text] [Related]  

  • 4. [Financial interests characterize published reports on coxiber. Whom can we rely on?].
    Håkansson J
    Lakartidningen; 2002 Oct; 99(40):3930-1. PubMed ID: 12422746
    [No Abstract]   [Full Text] [Related]  

  • 5. Celecoxib for rheumatoid arthritis.
    Megeff CE; Strayer SM
    J Fam Pract; 2000 Feb; 49(2):108-9. PubMed ID: 10718683
    [No Abstract]   [Full Text] [Related]  

  • 6. Selective COX-2 inhibition.
    Silas S; Clegg DO
    Bull Rheum Dis; 1999; 48(2):1-4. PubMed ID: 12024416
    [No Abstract]   [Full Text] [Related]  

  • 7. [New treatment of pain and fever in rheumatoid arthritis and arthrosis. The first cyclooxygenase-2 inhibitors show promising results].
    Oliw E; Wollheim FA
    Lakartidningen; 2000 Jun; 97(24):2942-4. PubMed ID: 10900877
    [No Abstract]   [Full Text] [Related]  

  • 8. NSAIDs, Helicobacter pylori, and Pandora's Box.
    Graham DY
    N Engl J Med; 2002 Dec; 347(26):2162-4. PubMed ID: 12501230
    [No Abstract]   [Full Text] [Related]  

  • 9. Are selective COX 2 inhibitors superior to traditional NSAIDs? Both the CLASS and VIGOR trials support the COX 2 hypothesis.
    Stover RR
    BMJ; 2002 Jul; 325(7356):161; author reply 161. PubMed ID: 12134855
    [No Abstract]   [Full Text] [Related]  

  • 10. [Results of the VIGOR study. Rofecoxib halves the complication rate].
    MMW Fortschr Med; 2001 Jun; 143(23):35. PubMed ID: 11460417
    [No Abstract]   [Full Text] [Related]  

  • 11. Right ballpark, wrong base: assessing safety of NSAIDs.
    Shaughnessy AF
    J Fam Pract; 2002 Jun; 51(6):538. PubMed ID: 12100777
    [No Abstract]   [Full Text] [Related]  

  • 12. [Relationship between NSAIDs and H. pylori in peptic ulcer diseases--is the eradication of H. pylori recommended in NSAIDs ulcer?].
    Ota S; Nakajima S; Bamba H
    Nihon Rinsho; 2005 Nov; 63 Suppl 11():565-8. PubMed ID: 16363602
    [No Abstract]   [Full Text] [Related]  

  • 13. Low prevalence of idiopathic peptic ulcer disease: an Italian endoscopic survey.
    Sbrozzi-Vanni A; Zullo A; Di Giulio E; Hassan C; Corleto VD; Lahner E; Annibale B
    Dig Liver Dis; 2010 Nov; 42(11):773-6. PubMed ID: 20444661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclooxygenase (COX-2) selective inhibitors. Any better than NSAIDs?
    Nguyen A; Chaiton A
    Can Fam Physician; 2001 Jul; 47():1398-400. PubMed ID: 11494927
    [No Abstract]   [Full Text] [Related]  

  • 15. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
    Lai KC; Chu KM; Hui WM; Wong BC; Hu WH; Wong WM; Chan AO; Wong J; Lam SK
    Am J Med; 2005 Nov; 118(11):1271-8. PubMed ID: 16271912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends in the prevalence of peptic ulcer disease and Helicobacter pylori infection in family physician-referred uninvestigated dyspeptic patients in Hong Kong.
    Xia B; Xia HH; Ma CW; Wong KW; Fung FM; Hui CK; Chan CK; Chan AO; Lai KC; Yuen MF; Wong BC
    Aliment Pharmacol Ther; 2005 Aug; 22(3):243-9. PubMed ID: 16091062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapy of arthrosis. Life threatening gastrointestinal events can be reduced].
    MMW Fortschr Med; 2001 Jun; 143(23):34-5. PubMed ID: 11460416
    [No Abstract]   [Full Text] [Related]  

  • 18. [Selective cox-2 inhibitors. Better tolerance than NSAID plus antacid].
    MMW Fortschr Med; 2004 Apr; 146(15):66. PubMed ID: 15373027
    [No Abstract]   [Full Text] [Related]  

  • 19. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
    Maetzel A; Krahn M; Naglie G
    Arthritis Rheum; 2003 Jun; 49(3):283-92. PubMed ID: 12794781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in peptic ulcer between the East and the West.
    Leong RW
    Gastroenterol Clin North Am; 2009 Jun; 38(2):363-79. PubMed ID: 19446264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.